What is the appropriate approach to evaluate and manage a 45-year-old male with incidentally detected reactive hepatitis C virus (HCV) RNA?

Approach to Incidentally Detected HCV RNA in a Healthy 45-Year-Old Male

Confirm active HCV infection with HCV antibody testing, assess liver disease severity, and initiate direct-acting antiviral therapy—this patient requires treatment regardless of fibrosis stage to prevent progression to cirrhosis, hepatocellular carcinoma, and death.

Immediate Diagnostic Confirmation

Since HCV RNA is already reactive (confirming active viremia), you should:

• Obtain HCV antibody testing to complete the diagnostic workup 1
• Quantitative HCV RNA level (likely already done, but confirm the viral load is documented)
• HCV genotyping is no longer universally required if using pangenotypic regimens, but obtain it if considering treatment duration modifications 2

Essential Pre-Treatment Evaluation

Assess Liver Disease Severity

This is critical and must be done before treatment decisions 3, 1:

• Liver biochemistry: ALT, AST, bilirubin, albumin, INR, platelet count
• Abdominal ultrasound to evaluate liver parenchyma and rule out hepatocellular carcinoma
• Fibrosis assessment using non-invasive methods:
  • FIB-4 score (age × AST / [platelet count × √ALT]): <1.45 excludes advanced fibrosis; >3.25 suggests advanced fibrosis 1
  • APRI score ([AST/ULN] × 100 / platelet count): >1.5 suggests significant fibrosis; >2 suggests cirrhosis 1
  • Transient elastography if available: <7.1 kPa excludes significant fibrosis; >12.5 kPa suggests cirrhosis 1

Screen for Co-morbidities

• Hepatitis B surface antigen and core antibody (HBV reactivation risk with treatment) 2
• HIV testing (affects disease progression and treatment considerations) 2
• Hepatitis A immunity (vaccinate if non-immune) 2

Risk Factor Assessment

• Detailed exposure history: injection drug use, blood transfusions before 1992, tattoos, sexual practices
• Alcohol consumption: counsel complete abstinence as any amount accelerates fibrosis 2
• If injection drug use identified: refer to addiction medicine specialist 3

Determine Acute vs. Chronic Infection

This distinction matters for monitoring strategy 3:

• If exposure occurred <6 months ago (needlestick, known exposure): This may be acute HCV

  • Monitor HCV RNA every 4-8 weeks for up to 6 months
  • 15-25% will spontaneously clear within 12-16 weeks
  • If no clearance by 6 months, treat as chronic infection

• If timing unknown or >6 months (most incidental cases): Treat as chronic HCV infection

Treatment Recommendations

All patients with confirmed HCV infection should be treated regardless of fibrosis stage 4, 2. The goal is sustained virologic response (SVR), which equals cure in >99% of cases.

First-Line Pangenotypic Regimens

Use simplified treatment without genotyping 5, 6:

• Glecaprevir/pibrentasvir: 8 weeks (treatment-naive without cirrhosis) or 12 weeks (with compensated cirrhosis)
• Sofosbuvir/velpatasvir: 12 weeks for all patients

These achieve >95% cure rates with minimal side effects 6.

Treatment Prioritization

While all patients should be treated, prioritize immediate treatment if:

• Advanced fibrosis (F3-F4) detected
• Risk of transmission to others (active injection drug use, sexual partners)
• Patient preference for immediate treatment 3, 4

Counseling and Prevention

Provide specific harm reduction education 3, 2:

• Do not share needles, syringes, drug preparation equipment
• Do not share razors, toothbrushes, nail clippers
• Cover open wounds
• Sexual transmission is low but increased in HIV-positive men who have sex with men
• Complete alcohol abstinence—no safe level exists 2
• Avoid hepatotoxic medications (high-dose acetaminophen) 3

Monitoring During Treatment

Simplified monitoring is now standard 5, 6:

• No routine on-treatment HCV RNA testing required for uncomplicated cases
• Monitor only for medication adherence and side effects
• Check for drug interactions if on other medications

Post-Treatment Follow-Up

• Confirm cure: HCV RNA testing 12 weeks after treatment completion (SVR12) 7, 2
• If cirrhosis present: Continue HCC surveillance with ultrasound ± AFP every 6 months indefinitely 2
• If no cirrhosis: No liver-specific follow-up needed after SVR 6
• Reinfection risk: If ongoing risk behaviors, retest annually 7

When to Refer to Specialist

Refer if 5:

• Decompensated cirrhosis (Child-Pugh B or C)
• Prior treatment failure
• Hepatitis B or HIV coinfection
• Significant renal impairment (eGFR <30 mL/min)
• Pregnancy
• Complex drug interactions

Critical Pitfall to Avoid

Do not delay treatment waiting for "significant fibrosis"—this outdated approach from the interferon era no longer applies. Modern DAAs are safe, highly effective, and prevent disease progression. Treatment is cost-effective even in early disease 4, 2, 8.